Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma

British Journal of Dermatology

Volumn 165, Issue 6, 2011, Pages 1197-1204

  Oh, S T ^a   Kim, H S ^a   Yoo, N J ^a   Lee, W S ^a   Cho, B K ^a   Reichrath, J ^b  

^a The Catholic University of Korea   (South Korea)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MATRIX METALLOPROTEINASE 14;

ARTICLE; BASAL CELL CARCINOMA; CELL NUCLEUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

BETA CATENIN; CARCINOMA, BASAL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 14; RISK FACTORS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 82255164103     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10506.x     Document Type: Article

References (48)

1. Bath-Hextall F, Leonardi-Bee J, Smith C, et al. Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer 2007; 121: 2105-8. (Pubitemid 47463176)
2. Brodland DG,. Diagnosis of nonmelanoma skin cancer. Clin Dermatol 1995; 13: 551-7. (Pubitemid 26101087)
3. Leppälä J, Kaarniranta K, Uusitalo H, et al. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007; 85: 566-8. (Pubitemid 47163120)
4. Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007; 6: 507-13.
5. Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005; 31: 318-23. (Pubitemid 43072987)
6. Vun Y, Siller G,. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 2006; 47: 169-71. (Pubitemid 44015148)
7. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009; 69: 1517-26.
8. Gooyit M, Lee M, Hesek D, et al. Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors. Chem Biol Drug Des 2009; 74: 535-46.
9. Dahmane N, Lee J, Robins P, et al. Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997; 389: 876-81. (Pubitemid 27462984)
10. Saldanha G, Ghura V, Potter L, Fletcher A,. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 2004; 151: 157-64. (Pubitemid 39061293)
11. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74. (Pubitemid 37328786)
12. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-8.
13. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5. (Pubitemid 24216953)
14. Strongin AY,. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 2006; 25: 87-98. (Pubitemid 43723985)
15. Seiki M,. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194: 1-11. (Pubitemid 36428879)
16. Etoh T, Inoue H, Yoshikawa Y, et al. Increased expression of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related to cancer aggressiveness. Gut 2000; 47: 50-6. (Pubitemid 30430411)
17. Doyle JL, Haas TL,. Differential role of beta-catenin in VEGF and histamine-induced MMP-2 production in microvascular endothelial cells. J Cell Biochem 2009; 107: 272-83.
18. Takahashi M, Tsunoda T, Seiki M, et al. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002; 21: 5861-7. (Pubitemid 35007236)
19. Hlubek F, Spaderna S, Jung A, et al. Beta-catenin activates a coordinated expression of the proinvasive factors laminin-5 gamma2 chain and MT1-MMP in colorectal carcinomas. Int J Cancer 2004; 108: 321-6. (Pubitemid 37541790)
20. Liu P, Yang J, Pei J, et al. Regulation of MT1-MMP activity by β-catenin in MDCK non-cancer and HT1080 cancer cells. J Cell Physiol 2010; 225: 810-21.
21. Cho S, Kim MH, Whang KK, et al. Clinical and histopathological characteristics of basal cell carcinoma in Korean patients. J Dermatol 1999; 26: 494-501. (Pubitemid 29434631)
22. Sexton M, Jones DB, Maloney ME,. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol 1990; 23: 1118-26.
23. Jacobs GH, Rippey JJ, Altini M,. Prediction of aggressive behavior in basal cell carcinoma. Cancer 1982; 49: 533-7. (Pubitemid 12213452)
24. Dixon AY, Lee SH, McGregor DH,. Factors predictive of recurrence of basal cell carcinoma. Am J Dermatopathol 1989; 11: 222-32. (Pubitemid 19159016)
25. De Rosa G, Barra E, Guarino M, et al. Fibronectin, laminin, type IV collagen distribution, and myofibroblastic stromal reaction in aggressive and nonaggressive basal cell carcinoma. Am J Dermatopathol 1994; 16: 258-67. (Pubitemid 24229379)
26. Saldanha G, Fletcher A, Slater DN,. Basal cell carcinoma: a dermatopathological and molecular biological update. Br J Dermatol 2003; 148: 195-202. (Pubitemid 36278957)
27. Rippey JJ,. Why classify basal cell carcinomas? Histopathology 1998; 32: 393-8. (Pubitemid 28231370)
28. Christian MM, Moy RL, Wagner RF, et al. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma. Dermatol Surg 2001; 27: 441-5. (Pubitemid 32436333)
29. Crowson AN,. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 19: S127-47. (Pubitemid 43172313)
30. El-Bahrawy M, El-Masry N, Alison M, et al. Expression of beta-catenin in basal cell carcinoma. Br J Dermatol 2003; 148: 964-70. (Pubitemid 36750789)
31. Yoshizaki T, Sato H, Maruyama Y, et al. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 1997; 79: 139-44. (Pubitemid 26425519)
32. Iida J, Wilhelmson KL, Price MA, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol 2004; 122: 167-76. (Pubitemid 38120271)
33. Ohtani H, Motohashi H, Sato H, et al. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer 1996; 68: 565-70. (Pubitemid 26414514)
34. Ishigaki S, Toi M, Ueno T, et al. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer. Jpn J Cancer Res 1999; 90: 516-22. (Pubitemid 29267705)
35. Kanayama H, Yokota K, Kurokawa Y, et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998; 82: 1359-66. (Pubitemid 28155399)
36. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999; 59: 467-73. (Pubitemid 29048885)
37. Kerkelä E, Ala-aho R, Lohi J, et al. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Cancer 2001; 84: 659-69. (Pubitemid 32239000)
38. Cohen PR, Schulze KE, Nelson BR,. Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer. Dermatol Surg 2006; 32: 542-51.
39. Weinberg RA,. The Wnt-β-catenin pathway contributes to cell proliferation. In: The Biology of Cancer (, Weinberg RA, ed). New York: Garland Science, 2007; 189-91.
40. Tilli CM, Van Steensel MA, Krekels GA, et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol 2005; 152: 1108-24. (Pubitemid 40933407)
41. Bravou V, Klironomos G, Papadaki E, et al. ILK over-expression in human colon cancer progression correlates with activation of beta-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J Pathol 2006; 208: 91-9. (Pubitemid 43025707)
42. Pizarro A, Benito N, Navarro P, et al. E-cadherin expression in basal cell carcinoma. Br J Cancer 1994; 69: 157-62. (Pubitemid 24021840)
43. Pizarro A, Gamallo C, Benito N, et al. Differential patterns of placental and epithelial cadherin expression in basal cell carcinoma and in the epidermis overlying tumours. Br J Cancer 1995; 72: 327-32.
44. Fuller LC, Allen MH, Montesu M, et al. Expression of E-cadherin in human epidermal nonmelanoma cutaneous tumours. Br J Dermatol 1996; 134: 28-32. (Pubitemid 26029660)
45. Kooy AJ, Tank B, De Jong AA, et al. Expression of E-cadherin, alpha- and beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. Hum Pathol 1999; 30: 1328-35. (Pubitemid 29534295)
46. Pizarro A,. E-cadherin expression in basal cell carcinoma: association with local invasiveness but not with metastatic inefficiency. J Cutan Pathol 2000; 27: 479-80.
47. Rudek MA, Figg WD, Dyer V, et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001; 19: 584-92. (Pubitemid 32112874)
48. Suojanen J, Salo T, Koivunen E, et al. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther 2009; 8: 2362-70.